Would you consider "adjuvant" pembrolizumab for a patient with muscle invasive bladder cancer who is cisplatin ineligible and found at surgery to have T4aN2M0 disease?

Topics: Genitourinary Cancers • Bladder Cancer • Medical Oncology

If so, for how long would you treat?

Answer from: Medical Oncologist at Academic Institution

This good question will be answered in the ongoing AMBASSADOR trial led by @Andrea B. Apolo at NCI (pembro vs observation phase 3 adjuvant trial). There is also another adjuvant IO trial: Checkmate-274 trial (nivolumab vs placebo), while IMvigor010 did not meet primary endpoint of DFS benefit w...

Comments

Medical Oncologist at AdventHealth Cancer Institute
I completely agree with the comments made by @Petr...

Related Questions